




FORM PTO-1449 INFORMATION DISCLOSURE STATEMENT				ATTORNEY DOCKET NO. PU4803US		SERIAL NO. 10/600,751	
				APPLICANT Randy K. BLEDSOE et al.			
				FILING DATE June 20, 2003		GROUP 1645 1656	
U.S. PATENT DOCUMENTS							
Examiner Initials		Patent Number	Issue Date	Name	Class	Subclass	Filing Date If Appropriate
Continue on page _____							
FOREIGN PATENT DOCUMENTS							
		Document Number	Publication Date	Country	Class	Subclass	Translation Yes No
WIS	1.	WO 00/52050	09/08/2000	WIPO			
WIS	2.	WO 02/36606	05/10/2002	WIPO			
WIS	3.	WO 03/015692	02/27/2003	WIPO			
Continue on page _____							
OTHER DOCUMENTS (Including Author, Title, Journal-Date, Page Number, Etc.)							
WIS	4.	Dey et al., "Homology modeling of the ligand-binding domain of glucocorticoid receptor: binding site interactions with cortisol and corticosterone," <i>Protein Engineering</i> 14(8):565-571 (2001).					
WIS	5.	Hollenberg et al., "Primary structure and expression of a functional human glucocorticoid receptor CDNA," <i>Nature</i> 318:635-641 (Dec. 1985).					
WIS	6.	Stevens, "High-throughput protein crystallization," <i>Current Opinion in Structural Biology</i> 10(5):558-563 (Oct. 2000).					
Continue on page _____							
EXAMINER 					DATE CONSIDERED 08-26-05		
EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP § 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to the applicant.							

FORM PTO 449 INFORMATION DISCLOSURE STATEMENT 				ATTORNEY DOCKET NO. PU4803US		SERIAL NO. 10/600,751	
				APPLICANT Randy K. BLEDSOE et al.			
				FILING DATE June 20, 2003		GROUP 1645 1656	
U.S. PATENT DOCUMENTS							
Examiner Initials		Patent Number	Issue Date	Name	Class	Subclass	Filing Date If Appropriate
Continue on page _____							
FOREIGN PATENT DOCUMENTS							
		Document Number	Publication Date	Country	Class	Subclass	Translation Yes No
Continue on page _____							
OTHER DOCUMENTS (Including Author, Title, Journal-Date, Page Number, Etc.)							
DS	1.	Bledsoe et al., "Crystal structure of the glucocorticoid receptor ligand binding domain reveals a novel mode of receptor dimerization and coactivator recognition," <i>Cell</i> 110(1):93-105 (Jul. 2002).					
DS	2.	Caamano et al., "The functional relevance of the heteromeric structure of corticosteroid receptors," <i>Annal. NY Acad. Sci.</i> 746:68-77 (1994).					
DS	3.	Matias et al., "Structural evidence for ligand specificity in the binding domain of the human androgen receptor," <i>The Journal of Biological Chemistry</i> 275(34):26164-26171 (Aug. 2000).					
DS	4.	Ohara-Nemoto et al., "The steroid-binding properties of recombinant glucocorticoid receptor: a putative role for heat shock protein hsp90," <i>J. Steroid Biochem. Molec. Biol.</i> 37(4):481-490 (Nov. 1990).					
DS	5.	Rajapandi et al., "The molecular chaperones hsp90 and hsc70 are both necessary and sufficient to activate hormone binding by glucocorticoid receptor," <i>The Journal of Biological Chemistry</i> 275(29):22597-22604 (Jul. 2000).					
DS	6.	Sack et al., "Crystallographic structures of the ligand-binding domains of the androgen receptor and its T877A mutant complexed with the natural agonist dihydrotestosterone," <i>Proc. Natl. Acad. Sci. USA</i> 98(9):4904-4909 (Apr. 2001).					
DS	7.	Williams et al., "Atomic structure of progesterone complexed with its receptor," <i>Nature</i> 393(6683):392-296 (May 1998).					
DS	8.	Xu et al., "Binding of hsp90 to the glucocorticoid receptor requires a specific 7-amino acid sequence at the amino terminus of the hormone-binding domain," <i>The Journal of Biological Chemistry</i> 273(22):13918-13924 (May 1998).					
Continue on page _____							
EXAMINER 					DATE CONSIDERED 8-26-05		
EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP § 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to the applicant.							